Rousselot and Gelomics to Create Ready-to-Use 3D Cell Culture Kits
Earlier this year, Rousselot Biomedical, a strategic segment established within Darling Ingredients (NYSE: DAR) in 2018, launched a cobranding program to pair its own expertise in biomedical gelatins with some of the top biotechnology companies in order to speed up the development of new medical devices and medicines. The latest cobranding partner in the program is Australia-based Gelomics, which provides fully integrated 3D cell, organoid, and tissue culture technologies. Together, the two will work to create what Rousselot says will be the world’s first ready-to-use 3D cell culture kits based on its X-PURE GelMA material.
“The broad uptake of modern 3D cell culture techniques in biomedical R&D has been slowed down by a lack of easy-to-use and reproducible biomaterials that enable cells to grow and behave in a physiological manner,” Christoph Meinert, the CEO of Gelomics, said in a press release. “We are pleased to partner with Rousselot Biomedical to overcome these limitations and provide the world’s first, ready-to-use 3D cell culture kits based on Rousselot Biomedical’s X-Pure GelMA.”
Rousselot, which is Darling Ingredients’ Health Brand, is dedicated to the advancement of medical science, and got its start developing ultra-pure collagen and gelatin solutions for biomedical applications, including regenerative medicines, vaccines, and hemostats. Now, it is a world leader in collagen-based solutions, and works with many industries, biomedical research companies, and startups that are looking for a medical-grade gelatin with excellent purity for in-body and research applications. Both its X-PURE and QUALI-PURE gelatin ranges are backed by strong scientific data and continuing research, but X-PURE GelMA, or gelatin methacryloyl, is what Gelomics will use with its LunaGel 3D Tissue Culture System.
“We are proud to partner with Gelomics, who share our passion and commitment to quality and collaboration. Leveraging the consistency and purity of X-Pure GelMA, the LunaGel X-Pure products offer Gelomics’ customers an easy-to-use solution for creating the optimal experimental conditions for cell culture,” explained Tanja Vervust, Director Rousselot Biomedical.
LunaGel, which is Gelomics’ first product series, is a photocrosslinkable cell culture system that replicates the natural extracellular matrix (ECM) which surrounds cells in the body. This means researchers can use the system to actually grow 3D microscopic tissues, instead of cells on plastic surfaces. The company prides itself on speeding up biomedical R&D by helping researchers and scientists grow human-like tissues in the lab that can improve cell-based research; this also helps decrease the requirements for experiments on animals, which is always good.

Gelatin methacrylate in general is used in many 3D bioprinting, 3D cell culture, and tissue engineering applications, due to its bioactivity and tuneability. Like LunaGel, Rousselot’s X-PURE GelMA is also photocrosslinkable, and is its own ECM. This biomaterial is ultra-pure (<10 Endotoxin Units (EU)/g), which means it can be used for very sensitive biomedical and pharmaceutical applications—including advanced therapy medicinal products (ATMP)—and is said to be the first GelMA produced under GMP conditions.
Using a GelMA hydrogel enables the formation of 3D architectures that are stable at body temperature, and you can customize X-PURE GelMA’s rheological properties by changing the gelatin molecular weight and the number of crosslinks between gelatin protein chains, which makes it an extremely versatile hydrogel for drug delivery systems and 3D cell culture.

Thanks to its cobranding partnership with Rousselot, Gelomics’ new LunaGel X-PURE GelMA product series will supposedly be the first premium, ultra-pure GelMA available in an easy-to-use format, and will be available as ready-to-use kits in both high and low stiffness formulations.
Images courtesy of Rousselot, unless otherwise noted.
3DPrint.com and SmarTech Analysis are hosting Additive Manufacturing Strategies in New York City from February 7-9, 2023. To learn more about bioprinting, 3D printing materials, and the technology’s use in the medical field, as well as network with the industry’s most exciting leaders and companies, you can register for the event here.
Subscribe to Our Email Newsletter
Stay up-to-date on all the latest news from the 3D printing industry and receive information and offers from third party vendors.
Print Services
You May Also Like
New Business: Temporary, Migratory, & Modular 3D Printed Architecture
If we look at potentially emerging 3D printing businesses, then architecture has not been fully explored. Yes, there is a lot of house 3D printing going on worldwide. From deployable...
Velo3D Kicks Off New Strategy by Signing $15M Deal with Space Company
Velo3D (OTCMKTS: VLDX) just landed a five-year, $15 million deal with commercial space company Momentus (Nasdaq: MNTS). But this partnership is more than just a revenue boost; instead, it marks...
3D Printing News Briefs, April 12, 2025: RAPID Roundup
The news from last week’s RAPID+TCT in Detroit just keeps on coming! That’s why today’s 3D Printing News Briefs is another RAPID Roundup of more exciting announcements from the trade...
Continuum Powders Turns Siemens Scrap Into High-Value 3D Printing Material
Over the last five months of 2024, Continuum Powders turned almost one ton of nickel scrap per week from Siemens Energy into high-quality metal powder, the kind used for 3D...